| Assessment Status | Rapid Review Complete |
| HTA ID | 20033 |
| Drug | Abemaciclib |
| Brand | Verzenios® |
| Indication | For the treatment of women with hormone receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. |
| Assessment Process | |
| Rapid review commissioned | 06/07/2020 |
| Rapid review completed | 27/08/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib (Verzenios®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
